Roche outlined how digital health technologies (DHTs) provide more sensitive measures of disease progression in early ...

The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to ...

Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...

Parkinson's disease overview, treatment options, including deep brain stimulation, and future developments in neurosurgery by ...

Parkinson's disease patients and advocates are marking Friday as the start of a new era for treatment of the illness as a ...

Clinical studies have revealed that rasagiline is associated with improved outcomes in patients with early Parkinson's disease ... to advanced PD with motor fluctuations. Rasagiline is rapidly ...

This investigational treatment was generally well tolerated with no serious adverse events; fewer adverse events related to non-motor symptoms were reported in the solengepras arm Pivotal Phase 3 ...

With over 10 million people affected worldwide, Parkinson's disease is the fastest-growing neurological disorder. More than ...

CervoMed (CRVO) announced that investigators plan to present results, including new results, from the Extension phase of the Phase 2b RewinD-LB ...

Two CU Anschutz researchers have been working with researchers across the globe to develop groundbreaking new technology ...

People who had Parkinson’s disease but not dementia ... such as psychosis and attentional fluctuations, that providers of hospice care are less familiar with, the authors pointed out.